This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Regeneron Highlights EYLEAA® (aflibercept) Injection Data To Be Presented At American Academy Of Ophthalmology Annual Meeting

Stocks in this article: REGN

TARRYTOWN, N.Y., Nov. 12, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from several studies of EYLEA ® (aflibercept) Injection will be presented during the annual meeting of the American Academy of Ophthalmology (AAO) to be held November 16-19 in New Orleans.  EYLEA presentations will be featured during the AAO scientific sessions ( November 16-19), as well as during the Retina Subspecialty Days ( November 15-16).

During the Retina Subspecialty Days, detailed results from the Phase 3 VIBRANT study of EYLEA in Macular Edema following BRVO will be presented for the first time.  Retinal vein occlusion is a common cause of vision loss in the elderly and the second most frequent major retinal vascular disease.(1)       

"Regeneron continues to study EYLEA across a range of eye diseases where Vascular Endothelial Growth Factor (VEGF) has demonstrated a role in disease development," said Robert Vitti, M.D., Vice President, Clinical Sciences, Ophthalmology, at Regeneron.  "The presentations at this year's AAO meeting reflect our commitment to continually provide data from the full spectrum of on-going research with EYLEA."

Abstracts include:

Friday, November 15 (Retina Subspecialty Day)

  • Intravitreal aflibercept for macular edema due to branch retinal vein occlusion:  24 week results of the VIBRANT study
    • Presenting author: W. Lloyd Clark, M.D.
    • Oral presentation at 1:51 p.m.; Morial Convention Center, Great Hall
  • Intravitreal aflibercept injection for diabetic macular edema: 12 month results of VISTA-DME and VIVID DME
    • Presenting author: Diana Do, M.D.
    • Oral presentation at 1:58 p.m.; Morial Convention Center, Great Hall
  • VEGF Trap-Eye (VIEW) sub-analysis: Influence of anatomic characteristics on outcomes
    • Presenting author: John Kitchens, M.D.
    • Oral presentation at 3:59 p.m.; Morial Convention Center, Great Hall

1 of 5

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs